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The use of rituximab for the treatment of immune thrombocytopeniawas greeted enthusiastically: it led to up to 60% response rates, mak-ing it, nearly 20 years ago, the main alternative to splenectomy, with
far fewer side effects. However, long-term follow-up data showed that only
20-30% of patients maintained the remission. No significant changes have
been registered using different dose schedules and timing of administration,
while the combination with other drugs seemed promising. Higher
response rates have been observed in young women before the chronic
phase, but apart from that, other clinical factors or biomarkers predictive of
response are still lacking. In this review we examine the historical and cur-
rent role of rituximab in the management of immune thrombocytopenia,
20 years after its first use for the treatment of autoimmune diseases.
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ABSTRACT
Introduction
Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder
due to a variable combination of increased platelet destruction and impaired
platelet production, as a consequence of defects in central and/or peripheral
immune tolerance which allow the escape of autoreactive lymphocytes.1–3 B cells
have a well-established role in the pathogenesis of the disease, as the source of anti-
bodies directed against platelet-surface glycoproteins.4–6
Rituximab, a monoclonal antibody directed against CD20, a membrane glyco-
protein expressed on the surface of B cells, was introduced for the treatment of B-
cell lymphomas towards the end of the 1980s.7
Binding to an antigen that is only expressed on mature B cells, rituximab leads to
a fast and deep, but reversible B-cell depletion.8 The transience of the B-cell deple-
tion and the low toxicity profile represented the rationale for its use in the treat-
ment of autoimmune conditions, especially those in which B-cell activity was con-
sidered the main pathogenic mechanism, such as ITP. Many studies have been car-
ried out in this field: in monotherapy, with different dose schedules and in combi-
nation with other drugs, proving its efficacy, although some differences exist across
certain studies.
Rituximab has also been explored in a number of other autoimmune auto-anti-
body-mediated diseases such as systemic lupus erythematosus,9 rheumatoid arthri-
tis,10 autoimmune hemolytic anemia,11 type II mixed cryoglobulinemia,12 myasthe-
nia gravis,13 multiple sclerosis,14 thrombotic thrombocytopenic purpura,15 Sjogren
syndrome,16 pemphigus17 and others. Despite these extensive investigations,
autoimmune conditions for which rituximab is licensed by the Food and Drug
Administration and the European Medicines Agency are rheumatoid arthritis and
ANCA-associated vasculitis. 
In this review, we discuss the development and current role of rituximab in the
management of ITP.
Pathophysiology of immune thrombocytopenia
The milestone role of autoantibodies in the pathogenesis of ITP was first report-
ed in 1951 by Harrington et al., who showed that the infusion of plasma from ITP
patients into normal controls caused thrombocytopenia,
thus imputing the cause of the disease to a plasma-derived
factor.4 This “factor” was subsequently identified as an
IgG anti-platelet antibody, directed against platelet glyco-
protein (GP) IIb/IIIa and/or the GPIb-IX-V complex.5 Very
rarely, antibodies against GPIa-IIa or GPIV can be found
(5%).18
Antibody-opsonized platelets are then recognized
through the Fcγ-receptors by macrophages in the spleen,
liver and bone marrow, phagocytized and prematurely
destroyed.19 Other mechanisms through which antibodies
can mediate platelet destruction are complement deposi-
tion with intravascular lysis and induction of platelet
apoptosis.20–23 Plasma from patients with ITP also inhibits
megakaryocyte growth and function in the bone mar-
row.6,24
The Ashwell-Morell receptors in hepatocytes have been
invoked as a further pathogenic mechanism, because they
physiologically remove desialylated, “old” platelets from
the circulation. Anti-GPIb/IX autoantibodies are thought
to enhance the desialylation of GPIb, increasing hepatic
clearance of platelets.25,26
Many abnormalities have been shown in T cells of
patients with ITP: an altered Th1/Th2 balance, with an
increased number of Th1 T-helper cells27,28 and a decrease
in the number and function of regulatory T cells.29,30 The
abnormal activation of cytotoxic CD8+ T cells may also
have a role in the pathogenesis of ITP, contributing to both
platelet destruction and impaired platelet production.31
Circulating thrombopoietin levels in ITP are not
increased proportionally to the level of thrombocytope-
nia, and are usually normal or only slightly increased.32
Early history of rituximab
In the late 1980s, the idea of using monoclonal antibod-
ies that recognize tumor-associated antigens for the treat-
ment of hematologic malignancies became reality, and rit-
uximab became a well-tolerated and highly effective
option initially used for patients with multi-refractory lym-
phoproliferative diseases.7 CD20, a transmembrane glyco-
protein expressed on the surface of normal and malignant
B cells, appeared ideal for targeted therapy, because it does
not shed from the cell surface and is not internalized upon
antibody binding.33 CD20 is expressed from early pre-B to
mature B lymphocytes, but is not expressed on hematopoi-
etic stem cells, plasma cells or other cells of the body.34
Rituximab is a type 1 IgG1-κ human-mouse chimeric
mono clonal antibody directed against CD20, which acts
through three mechanisms: complement-dependent cyto-
toxicity, antibody-dependent cellular cytotoxicity and
induction of direct apoptosis of the target cell.35
The first report of a case in which rituximab was used
for the treatment of an autoimmune disease was pub-
lished in 1998, when a patient with a cold agglutinin dis-
ease and a small IgM paraprotein was successfully treated
with four weekly infusions of rituximab.36 A few years
later, in 2001, the first report of the successful use of ritux-
imab for the treatment of ITP associated with a low-grade
non-Hodgkin lymphoma was published.37 Since then, rit-
uximab has been widely used for the treatment of autoim-
mune manifestations associated with lymphoproliferative
disorders, and, because it is a therapy borrowed from lym-
phomas, the dose schedule of 375 mg/m2 weekly for 4
weeks also became the “standard dose” of rituximab in
autoimmune diseases.
Since CD20 is also expressed in normal B cells, there
was a strong rationale for using rituximab to deplete
pathological antibodies in autoimmune diseases. One of
the first cases, published in 2000, was that of a young man
with refractory myasthenia gravis who, after four stan-
dard doses of rituximab, experienced a complete clinical
response with disappearance of anti-acetylcholine recep-
tor antibodies, and he did not relapse.13 This case was an
impressive proof of principle that transient B-cell deple-
tion secondary to rituximab treatment may positively
modulate the immune system, inhibit the production of
autoantibodies, and cause long-term clinical improve-
ment.
Rituximab in immune thrombocytopenia
In 2001, Stasi et al. reported the results of the first
prospective study in which 25 patients with chronic ITP
were treated with four weekly infusions of rituximab at a
dose of 375 mg/m2. The overall response rate (ORR) was
52%, with 28% sustained responses. No clinical or labo-
ratory parameters were found to predict treatment
response, but they noticed that women and younger
patients had a better chance of response, and that, in some
patients who relapsed, retreatment was effective.38
Subsequent studies showed that the overall initial
response to rituximab used as second- or further-line of
therapy ranges between 52% and 73%, with the complete
response (CR) rate ranging between 20% and 54%39-48, 56, 58,
68 (Table 1). In a systematic review including 313 adult
patients with chronic ITP, a response rate of 62.5% and a
CR rate of 46.3% were found, with a median duration of
response of 10.5 months.42
Three different patterns of response can be distin-
guished: a first group of patients respond rapidly, within
the first month; in the second group, the platelet count
starts increasing after 3-4 weeks, and a CR is achieved
within 8 weeks after treatment; in the third group of
patients, the platelet count increases very slowly, only
reaching normal values 3 months after therapy.46
Only two randomized, placebo-controlled studies have
been performed. One very small pilot randomized trial
compared rituximab with placebo as second-line therapy.
No difference in terms of treatment failure (65.6% vs.
80.8%)47 was found between the two groups. Overall
platelet count response (i.e. platelet count ≥30x109/L) was
achieved by 62.5% of the patients in the rituximab group
and 73.1% in the placebo group at 6 months. 
In the much larger RITP trial,48 the rate of treatment fail-
ure was not significantly different between patients given
rituximab or placebo (58% vs. 69%), and the ORR was
81% in the rituximab group compared to 73% in the
placebo group. Improvements in platelet counts were seen
up to week 72 in the rituximab arm. 
Rituximab doses
“Standard dose” rituximab results in a marked reduction
of malignant and non-malignant B cells in peripheral blood
and bone marrow.49 Since the total mass of B cells is much
smaller in patients with ITP than in patients with lym-
phoma, it was not clear whether a lower dose of ritux-
imab or a different schedule could be equally effective.
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Potential advantages of the lower dose include avoidance
of severe side effects, steroid-sparing effects, the greater
possibility of administering repeated courses, and
decreased cost. Zaja et al. investigated the efficacy of ritux-
imab given at a dose of 100 mg (“low dose”) weekly for 4
weeks in 48 ITP patients.50 In an indirect, non-randomized
comparison, both the initial response (ORR 60.5% and CR
39.5%) and the duration of response (12- and 24-month
cumulative relapse-free survival rates of 61% and 45%,
respectively) were moderately lower in this group than in
patients treated with “standard dose”. The time to
response was also longer than that observed with the
“standard dose”. This may be due to the fact that the
depth of B-cell depletion reached in peripheral blood
might not correlate with the depletion in other organs,
and the 100 mg dose is probably not enough.
A recent UK study retrospectively compared 113
patients who received “standard dose” rituximab to 169
who received the “low dose”. They found that the low
dose was not significantly different from the standard
dose with regards to ORR (at 2 months, 56% vs. 59%; at
6 months, 62% vs. 64%), time to maximum platelet count
(77 vs. 74 days), time to next treatment (4.6 vs. 4.3 months)
and duration of response.51
Some groups explored a fixed dose of rituximab, 1000
mg given twice on days 1 and 15, which is the dose sched-
ule licensed for rheumatoid arthritis. Khellaf et al., in a
prospective registry including 248 patients, compared the
“standard dose” to the “rheumatoid arthritis-like” regi-
men. They did not find any difference in terms of initial or
long-term response between the two groups.41 In a multi-
center, single-arm study (R-ITP1000 study), Tran et al.
found that the “rheumatoid arthritis-like” fixed dose led to
an ORR of 44% at week 8 in patients with relapsed/refrac-
tory ITP.52
A multicenter, randomized, phase II Dutch trial com-
pared three rituximab dosing schemes in 156 patients
with relapsed or refractory ITP: “standard dose” ritux-
imab, two weekly 375 mg/m2 doses and two weekly 750
mg/m2 doses. Response rates were similar within the three
arms (63%, 59% and 61%, respectively), with a relapse-
free survival of 72% at 1 year and 58% at 2 years.53
The results of the most relevant studies with different
dosing schedules of rituximab are summarized in Table 2.
Factors predictive of response
Over the years, multiple factors have been investigated
with the aim of predicting response to treatment.  Several
studies highlighted the correlation of age and gender with
outcome. In the very first study, Stasi had already pointed
out that women and young patients had better responses.38
This finding was subsequently extended by Bussel et al.,54
who showed that women of child-bearing age whose
duration of ITP was less than 24 months had a long-term
response comparable with that obtained after splenectomy
(60% long-term treatment-free responses). Another study
with the same treatment schedule pointed out that adoles-
cent females with an ITP duration of less than 12 months
had the longest duration of response.55 Similar results were
also reported with rituximab alone: young (<40 years)
women had a significantly higher probability of achieving
a response (73%), a complete response (56%), and as well
as a better long-term response (47% after 72 months) com-
pared with the other groups.56 It must be noted, however,
Table 1. Most relevant studies with rituximab administered at a standard dose of 375 mg/m2 weekly for 4 weeks in patients with immune thrombocytopenia. 
Author            Number of    Median age,      F:M         ITP phase                          ORR             6 months      12 months  24 months   36 months     Last follow-up
                         patients      years (range)
Stasi 200138               25                46 (22-74)      64%:36%      Chronic                          52% (20% CR)°            NA                     NA                  NA                   NA              NA
Cooper 2004£, 46        57                46 (21-79)      68%:32%      Chronic                                    54%                       NA                     NA                  NA                   NA              32% at a median FU of
                                                                                                                                                    (32% CR)°                                                                                                               72 weeks (18 months)
Zaja 2006£, 58               37                       NA                  NA            Median ITP                             73%                       NA                     NA                  NA                   NA              40.5% at a median FU 
                                                                                                       duration: 34.5                   (54% CR)°                                                                                                               of 25 months (3-55)
                                                                                                       (1-264) months
Medeot 2008£, 68        26                55 (18-76)      81%:19%      Median ITP                             69%                       NA                    55%                45%                 41%             35% at a median FU
                                                                                                      duration 34.5                    (54% CR)°                                                                                                               of 57 months
                                                                                                       (4 - 264) months                       
Godeau 2008£, 39        60                48 (18-84)      67%:33%      Chronic                                     NA                        NA         40% (30% CR)°      33%                  NA              NA
Cervinek 2012£, 43     114               55 (21-89)      53%:47%      16% ND; 84% chronic            NA            72% (48% CR)*   ORR 69%            NA                   NA              NA
                                                                                                       or persistent phase                                                                 (45% CR)
Patel 2012£, 40             72                39 (18-78)      65%:35%      Most chronic phase             57%°                      NA                    38%                31%                  NA              21% at 5 years FU
Arnold 2012£, 47          33                40 (30-59)      58%:42%      50% ND                                      NA           62.5% (53% CR)*        NA                  NA                   NA              NA
Mahevas 2013£, 45      61                52 (34-70)      64%:36%      18% ND; 26%                          54%                       NA          36% (28% CR)        NA         31% (26% CR)    NA
                                                                                                       persistent phase;            (32% CR)                                                                                  median FU of
                                                                                                       56% chronic phase        at 3 months*                                                                                  36 months
Khellaf 2014$, 41        173               51 (21-71)      64%:36%      56% chronic                           62%*                     80%                   62%                50%                 38%             NA
Ghanima 2015$, 48      55                46 (27-61)      73%:27%      33% ND; 24%                           73%                     60%                   45%                 NA                   NA              24% at 78 weeks FU
                                                                                                       persistent phase;           (51% CR)*
                                                                                                       44% chronic phase                    
Marangon 2017£, 56   103               46 (15-82)      59%:41%      Median ITP duration            55%                       NA                     NA                 42%                 40%             21% at 96 months
                                                                                                       20 (1 - 403) months         (36%CR)*                                                                                               
F:M: female to male ratio;  ITP: immune thrombocytopenia; ORR: overall response rate; CR: complete response; NA: not available; FU: follow-up; ND: newly diagnosed. £Considering as denominator
all the patients.$Considering as denominator only patients who responded to rituximab. *response = platelet count ≥30x109/L. °response = platelet count ≥50 x 109/L
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that in several other studies the predictive role of age and
gender could not be confirmed.40,41,43,46,57 A disease duration
of less than 12 months has also been frequently related to
better outcomes,41,43,54,58 as well as the achievement of com-
plete remission,39,40,46,54,56 while the influence of a previous
splenectomy is not completely clear.40,46
The role of antiplatelet autoantibodies (APA) as factors
predictive of response is controversial. Differently from
other autoimmune diseases, APA in ITP are neither very
specific nor sensitive, and for this reason APA are not cur-
rently recommended as a diagnostic test for ITP.59,60 A reduc-
tion of APA levels has been associated with an increase in
platelet count,61 and the presence of platelet-bound antibod-
ies has been associated with a better response to ritux-
imab.62 The persistence of autoantibodies in non-respon-
ders may suggest that rituximab had not removed the long-
lived, antibody-producing plasma cells. There is also a small
cohort of patients who respond despite undetectable anti-
bodies: in those cases, either laboratory assays are not able
to identify the antibody, or the response comes from the
elimination of B-cell-mediated activation of T cells.61
A more recent study did not show any correlation
between the presence of APA and the response to ritux-
imab, but found that rituximab resulted in a significant
reduction of anti-GPIIb/IIIa but not anti-GPIb/IX levels.63
In an unconfirmed study, patients with anti-GPIb/IX were
shown to have a lesser response to intravenous
immunoglobulins and steroids.64,65 In patients treated with
rituximab, the presence of antibodies against GPIIb/IIIa
led to a higher response rate than that in patients without
anti-GPIIb/IIIa, while the presence of anti-GPIb/IX did not
significantly influence the outcome.66 This is potentially
due to the different modes of action of the autoantibodies:
anti-GPIIb/IIIa antibodies induce platelet destruction by
Fc-dependent phagocytosis, while the action of anti-
GPIb/IX may be FcR-independent67 and instead increase
the hepatic clearance of desialylated platelets. 
In summary, the role of APA in response to rituximab
remains unclear and may depend on the laboratory doing
the testing, the phase of the disease, and which tests are
performed.
Long-term outcome of rituximab treatment of immune
thrombocytopenia
Only a small proportion of patients maintain a long-
term remission after rituximab: in a prospective French
Table 2. Most relevant studies with different dose schedules of rituximab.
Author                    Rituximab        Number      Median age,     F:M          ITP phase                Early         6 months    12 months    24 months  36 months  Last follow-up
                                    dose          of patients   years (range)                                                 response
Mahevas 2013£,45         375 mg/m2               61               52 (34-70)     64%:36%          ND 18%;             54% (32% CR)          NA                  36%                  NA                  NA          31% (26% CR)
                                      weekly x 4                                                                               P 26%; C 56%         at 3 months*                             (28% CR)                                                       Median FU 
                                                                                                                                                                                                                                                                                                          36 months
                               1000 mg on days 1        46               55 (34-76)     67%:33%          ND 17%;            54% (32% CR)          NA                  50%                  NA                  NA          48% (41% CR)
                                          and 15                                                                                         P 26%;              at 3 months*                            (41% CR)                                                       Median FU
                                                                                                                                               C 57%                                                                                                                                             20.5 months
Khellaf 2014$,41            375 mg/m2              173              51 (21-71)     64%:36%      56% chronic                 62%*                 80%                 62%                 50%                38%                    NA
                                      weekly x 4                 
                                        1000 mg                 72               53 (33-73)     65%:35%      66% chronic                 61%*                 90%                 70%                 43%                   /                       NA
                                   2 weeks apart              
Tran 201452           1000 mg on days 1       108              49 (19-85)     57%:43%       Median ITP       43.5% (CR 9.3%)        NA                 29%£                  NA                  NA                     NA
                                          and 15                                                                                       duration               at week 8°                                    66%$
                                                                                                                                         24.8 months
                                                                                                                                           (1.2 - 470)
Zaja 2010$,50            100 mg weekly x 4        48               41 (16-74)     62%:38%       Median ITP     60.5% (CR 39.5%)°      NA                  61%                 45%                40%                    NA
                                                                                                                                             duration 
                                                                                                                                           16 months 
                                                                                                                                            (2 - 451)
Zaja 2012£,44            100 mg weekly x 4        25               43 (14-74)          NA            Median ITP        52% (28% CR)*         NA                  32%                 28%                23%                23% at 
                                                                                                                                             duration                                                                                                                                            48 months
                                                                                                                                           24 months
                                                                                                                                              (2-324)
                             375 mg/m2 weekly x 4     32               51 (16-80)          NA            Median ITP        66% (50% CR)*         NA                  50%                 45%                40%                35% at 
                                                                                                                                             duration                                                                                                                                            48 months
                                                                                                                                           31 months 
                                                                                                                                              (3-264)
Gracie 2018$,51       100 mg weekly x 4       169              57 (30-70)     57%:43%       Median ITP                    NA                  61.7%               60%                 53%                50%                    NA
                                                                                                                                             duration                                         (35% CR)*
                                                                                                                                          12.9 months 
                                                                                                                                              (3.1-62)
                            375 mg/m2 weekly x 4    113              59 (35-72)     42%:58%       median ITP                    NA                  64.1%               60%                 51%                40%                    NA
                                                                                                                                             duration                                         (42% CR)*
                                                                                                                                           12 months 
                                                                                                                                           (2.9-43.5)                         
F:M: female to male ratio;  ITP: immune thrombocytopenia; ND: newly diagnosed; P: persistent phase ITP; C: chronic phase ITP; NA: not available; CR: complete response; FU: follow-up. $Response
rates calculated considering as denominator only patients who responded to rituximab.  £Response rates calculated considering as denominator all treated patients. *response = platelet count
≥30x109/L ° response = platelet count ≥50x109/L
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study in 248 adult patients, Khellaf et al. found that after a
median follow-up of 24 months, 39% of patients were still
responding.41 In other studies a long-term response, at
approximately 2 years after initial treatment, was
observed in about 40% of patients.39,56,68 However, the only
study with a 3-5 year follow up showed that the response
was maintained after 5 years in only 21% of adults and
26% of children treated with rituximab.40
Given that a long-term response greater than 20-30%
would be desirable, several strategies have been imple-
mented in order to augment response rates and sustained
remissions.
Anticipated use of rituximab in patients with immune
thrombocytopenia
Although not supported by randomized, controlled tri-
als, some studies pointed out that better outcomes can be
achieved if rituximab is administered in an early stage of
the disease.46,58 Following this observation, two studies69,70
compared the combination of “standard dose” rituximab
and dexamethasone (40 mg/day for 4 days) to dexametha-
sone alone as first-line therapy in adult patients with ITP.
In both studies the combination led to higher sustained
response rates (63%69 vs. 36% and 58%70 vs. 37%), com-
pared to those achived with dexamethasone alone.
Combination treatment to improve long-term outcome
with rituximab
Since rituximab affects almost exclusively B cells, with-
out directly affecting the activity of other cells of the
immune system (in particular T cells and plasma cells), the
combination with other drugs with different modes of
action looked appealing. The addition of 28 mg/m2 dex-
amethasone (as an anti-plasma cell treatment), given for
three 4-day cycles at 2-week intervals, to “standard-dose”
rituximab was explored in a cohort of 67 patients (41
adults and 26 children) with ITP, of whom only five were
treatment-naïve. This combination led to a 75% initial
response rate and an almost 50% estimated long-term
cure rate at 5 years.54 However, the good long-term
responses were seen almost exclusively in women of
child-bearing age within 1 year of diagnosis.
The combination of high-dose dexamethasone, low-
dose rituximab and cyclosporine (TT4) administered over
1 month was tested in 20 ITP patients (including 7 with
newly diagnosed ITP and 5 with secondary ITP), with the
aim of targeting, in addition to B cells, also plasma cells
and T cells. The response rate at 6 months was 60% and
among responders, the relapse-free survival rate was 92%
at 12 months and 76% at 24 months. The treatment was
well tolerated.71
Two Chinese studies explored the combination of low-
dose rituximab with recombinant human thrombopoietin.
The first study enrolled 14 patients with refractory ITP,
who had an ORR of 93%.72 The second was a random-
ized, open-label study in which the combination was
compared with rituximab 100 mg weekly for 4 weeks in
patients with relapsed or refractory ITP. The group treated
with the combination had a substantially shorter time to
response (7 vs. 28 days).73 The long-term response rate
(79.2% vs. 71.1%) was not significantly different between
the two groups. 
Gómez-Almaguer et al. recently published the results of
a single-center, pilot study conducted to assess the safety
and efficacy of the combination of eltrombopag, low-dose
rituximab and dexamethasone in 13 newly diagnosed ITP
patients. The ORR was 100%, with 92% CR rate and a
relapse-free survival rate of almost 80% at 12 months.74
The results of the most relevant studies of the use of rit-
uximab in combination with dexamethasone and other
drugs in ITP are summarized in Table 3a and 3b, respec-
tively.
Efficacy of rituximab retreatment
Limited data are available concerning retreatment with
rituximab. In a retrospective study, Hasan et al. explored
the response to retreatment with standard-dose rituximab
in patients with chronic ITP: 80% of the retreated patients
responded again to standard-dose rituximab.75
Zaja et al. showed that even low-dose rituximab can be
effective in patients who previously responded to the
standard dose of the drug, although only three patients
received a second course of rituximab.50 Khellaf et al.
reported that most of 11 patients retreated with rituximab
responded again.41 In other studies, very small numbers of
patients were retreated with rituximab, in most of cases
with good responses.38,56,68,76–78
Rai et al., in 17 patients with autoimmune cytopenias
(including 11 cases of ITP) who previously responded, but
then relapsed after a standard course of rituximab,
explored the use of rituximab maintenance: a single 375
mg/m2 infusion every 4 months for a total of 2 years: 88%
of patients achieved a CR, with a mean duration of
response of 48 months.79
B-cell recovery after rituximab
The depletion of circulating B cells after rituximab
administration is rapid (within 1 week) and deep, with B-
cell counts remaining low in the peripheral blood for at
least 6-12 months.8 The repopulating pool is dominated
by immature B cells, while memory B cells recover after 2
years.80 A similar depth of peripheral B-cell depletion has
also been observed with low-dose rituximab.50 In the vast
majority of patients who achieve a complete remission,
the recovery of B cells is not associated with disease
relapse,46 while in non-responders or in patients who
relapse, B cells tend to reappear sooner in the peripheral
blood and increase to higher levels.40,46 Rituximab also
induces nearly complete depletion of splenic B cells, and in
patients who do not respond the recovery of B cells in the
spleen is faster.81
Effects of rituximab on T cells
In rituximab responders, all the immune-system abnor-
malities seen in patients with active disease tend to revert
towards normal: in the peripheral blood, there is restora-
tion of the Th1/Th2 and Tc1/Tc2 ratios, a decreased
expression of Fas ligand and Bcl-2 mRNA, an increased
expression of Bax mRNA and an increased number of reg-
ulatory T cells82,83. The numbers of interleukin-10-produc-
ing B cells (regulatory B cells) and interleukin-6-producing
B cells are also normalized after treatment.84
In contrast, these abnormalities are still detectable in the
spleens of non-responders: reduced regulatory T cells, an
increased Th1/T-regulatory cell ratio,81 and persistence of
the Tc1 polarization with CD8+ cytotoxic T cells display-
ing the phenotype of effector memory T cells with a
restricted T-cell receptor repertoire.85 These findings sug-
gest that the action of rituximab is not limited to B cells
and humoral immunity, but that rituximab also affects cel-
E. Lucchini et al.
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lular immunity. In a mouse model of T-cell-mediated ITP,
B-cell depletion resulted in a significantly decreased prolif-
eration of splenic CD8+ T cells in vitro, which correlated
with an in vivo normalization of platelet counts.86
However, T-cell remodulation in responders seems not
to be a specific effect of rituximab since similar changes
have also been observed in patients who respond to dex-
amethasone or thrombopoietin receptor agonists.87–89 It is
possible that other biological factors concur to this effect.
In particular, it has been proposed that the platelet count
increase itself, either directly or via release of transforming
growth factor-b, may cause a positive immune-modulat-
ing effect.90
Why a proportion of patients do not respond to ritux-
imab is unknown. This could be caused by either the per-
sistence of long-lived, antibody-secreting plasma cells in
the spleen81,91 and/or in the bone marrow or by the abnor-
mal activation of T cells, whose activity is not switched
off by B-cell depletion. Finally, if the patient does not actu-
ally have ITP this would likely explain non-response as
well.
Adverse events
Rituximab is generally a well-tolerated therapy, and
adverse events are usually mild and easily manageable.
The major concerns derive from the possible induction of
hypogammaglobulinemia, and the increased risk of cer-
tain infections.
Infusion reactions after the first administration of ritux-
imab are experienced by a variable proportion of patients,
ranging from nearly 60% in the first trials46 to 15% in the
more recent reports,41 and are related to immediate
cytokine release. They are usually easily manageable, and
Table 3a. Studies with rituximab plus dexamethasone.
Author                       Treatment      Number       Median age,                    ITP phase        Early           6 months     12 months  24 months     36 months       Last follow-up
                                                     of patients    years (range)     F:M                            response
Zaja 201069                    375 mg/m2 x          49                49 (33-65)    55%:45%      Previously      37%° at                 63%                  50%                47%                   43%              43% 30-months 
                                       4 weekly + 1                                                                           untreated        week 4                                                                                                                       estimated 
                                         cycle dexa                                                                                                                                                                                                                                           probability
                                         (40 mg/day                                                                                                                                                                                                                                           of duration
                                         for 4 days)                                                                                                                                                                                                                                          of response
Gudbrandsdottir          375 mg/m2            62                51 (36-63)    58%:42%            ND                  NA                    57%°                 53%                 NA                     NA                           NA
201370                                               x 4 weekly +
                                      up to 6 cycles
                                dexa (40 mg/day for 
                                      4 days every 1
                                       to 4 weeks)
Bussel                          375 mg/m2 x           41                36 (18-64)    53%:46%     Median ITP      88% at                  82%                  65%                58%                   50%              47% estimated
201454                                    4 weekly + 3 cycles                                                                    duration: 16    week 8°                                                                                                                      sustained
                                dexa (28 mg/m2/day                                                               (1-286) months                                                                                                                                    response at 
                                         for 4 days)                                                                                                                                                                                                                                        64 months FU
Chapin 201655                           375 mg/m2 x          49                        37            55%:45%     Duration of          NA                      NA                    NA                  NA                     NA              33.3% sustained
                                 4 weekly + 3 cycles                                                                     ITP: range                                                                                                                                         response at
                                 dexa (28 mg/m2/day                                                                0 – 258 months                                                                                                                                  72 months FU°
                                         for 4 days)                                         
F:M: female to male ratio;  ITP: immune thrombocytopenia; dexa: dexamethasone; ND: newly diagnosed; NA: not available; FU: follow-up; yrs: years. Response rates are calculated using as denom-
inator all the patients treated with rituximab.°response = platelet count ≥50x109/L
Table 3b. Studies with rituximab in combination with drugs other than dexamethasone.
Author                  Treatment                                        Number   Median age,        F:M              ITP phase                      ORR             6 months   12 months     24 months
                                                                                       of patients  years (range)
Zhou 2015£,73            Rituximab 100 mg weekly for                     77             42 (13-82)       65%:35%            Median ITP               93% (50% CR)*         67.2%             24.6%                   NA
                                   4 weeks + rhTPO 300 μg/kg/day                                                                                         duration 
                                   for 14 days                                                                                                                     12.5 months (3-72)
                                   Rituximab 100 mg weekly                           38           42.5 (12-68)      66%:34%            Median ITP               93% (50% CR)*         55.6%             18.5%                   NA
                                   for 4 weeks                                                                                                                             duration                                
                                                                                                                                                                             11 months (3-65)
Choi 2015$,71             Rituximab 100 mg weekly for 4 weeks    20                   NA              55%:45%      ND or Persistent                      NA                     60%*               92%                   76%
                                   + dexa 40 mg days 1-4 + cyclosporine                                                                ITP: 7; Chronic ITP: 13
                                   2.5-3 mg/kg/day (days 1-28)                          
Li 2015£,72                  Rituximab 100 mg weekly for 4 weeks    14             52 (18-76)        93%:7%               Unknown                 93% (50% CR)* 71% (40% CR)       NA                     NA
                                   + rhTPO 300 μg/kg/day for 14 days            
Gomez-Almaguer  Eltrombopag 50 mg/day, days 1-28            13             40 (16-61)       62%:38%                   ND                      100% (92% CR)*           NA                 80%                   70%
2017£,74                       + dexa 40 mg days 1-4 + rituximab
                                   100 mg weekly for 4 weeks
F:M: female to male ratio;  ITP: immune thrombocytopenia; ORR: overall response rate; rhTPO: recombinant human thrombopoietin; CR: complete response; NA: not available; dexa: dexamethasone;
ND: newly diagnosed. $Response rates calculated considering as denominator only patients who responded to rituximab. £Response rates calculated considering as denominator all treated patients.
*response = platelet count ≥30x109/L; °response = platelet count ≥50x109/L.
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serious adverse reactions are exceptional, especially if
prednisone is included in premedication. 
Serum sickness is a much rarer adverse reaction, charac-
terized by fever, rash, polyarthralgia or arthritis, protein-
uria, hematuria, elevated inflammatory markers and
decreased complement, which usually arises 10-14 days
after treatment.92 It is the result of immune activation
against the chimeric mouse-human drug, with the forma-
tion and deposition of immune complexes, and conse-
quent activation of the complement cascade.93 This type
III delayed hypersensitivity reaction to rituximab has been
reported more commonly in autoimmune disorders than
in hematologic malignancies, but overall it remains a very
rare occurrence in adults, with less than 50 cases having
been reported.92
Hypogammaglobulinemia
Since rituximab does not affect pre-existing long-lived
plasma cells, there are not significant changes in the IgG or
IgM levels in patients treated with one “standard dose”
course.38,46–48 However, patients treated with multiple
courses are more likely to develop hypogammaglobuline-
mia, which usually recovers spontaneously in a few
months.94 Since dexamethasone also affects plasma cells,
10-20% of patients treated with the combination may
experience a marked hypogammaglobulinemia, which
usually recovers within 1 year.50,54,70
Some reports suggest that a pre-existing hypogamma-
globulinemia can be aggravated by rituximab, which can
in some cases trigger or accelerate the development of a
real common variable immunodeficiency (CVID).95,96 It is
worthwhile remembering that ITP may be the initial man-
ifestation of CVID and can precede its diagnosis by
years.97 It is therefore important, in ITP patients treated
with rituximab, to monitor immunoglobulin levels before
and after therapy. In addition to monitoring and possibly
even temporarily giving intravenous immunoglobulin
replacement, prior assessment of genetic markers and vac-
cine responses98,99 may be useful.
The efficacy and safety of standard-dose rituximab in
patients with CVID-associated ITP or autoimmune
hemolytic anemia was assessed in a multicenter, retro-
spective, French study. The ORR was 85%, with a 74%
CR rate and a sustained response rate of 60% at a median
follow up of 39 months; severe infections occurred in 24%
of patients, four of whom were not on immunoglobulin
replacement therapy. The authors concluded that ritux-
imab is highly effective and relatively safe in the manage-
ment of CVID-associated immune cytopenias, and that
immunoglobulin replacement is strongly recommended in
this cohort of patients.100
Infections
An increased risk of infections after rituximab therapy is
generally uncommon and more frequently observed in
severely immunocompromised patients.101 Chugh et al., in
a meta-analysis including five trials and 463 ITP patients
treated with rituximab, did not find an increased risk of
infection.102 Khellaf et al. concluded that the risk of infec-
tions was acceptable (cumulative incidence of 2.3 infec-
tions per 100 patient-years at a median follow up of 24
months), with the most severe infections occurring in
adults older than 70 years of age, who suffered from
severe comorbidities.41
Rituximab therapy reduces the genesis of new long-
lived plasma cells, thus impairing the immune response to
vaccines. Vaccines against encapsulated bacteria
(Streptococcus pneumoniae, meningococci and Haemophilus
influenzae) should be administered before rituximab, con-
sidering that patients, especially non-responding ones,
may require a subsequent splenectomy.103
Reactivation of hepatitis B virus (HBV) is a well-recog-
nized complication of immunosuppressive therapy.
Patients who are HBcAb positive (likely occult carriers)
should receive antiviral prophylaxis with lamivudine,
while patients with HBsAg or HBV-DNA positivity (active
carriers and inactive carriers) should be referred to a hepa-
tologist and treated with entecavir or tenofovir.104
A rare but life-threatening infection that has been linked
to rituximab is progressive multifocal leukoencephalopa-
thy (PML), caused by the activation of Jakob-Creutzfeld
virus and its spread to the central nervous system.105 This
complication, although rare, has been almost only report-
ed in patients with lymphoproliferative disorders, and
only a very few cases have been observed in patients with
autoimmune diseases, especially in systemic lupus erythe-
matosus.106,107 Furthermore, patients who develop PML are
usually profoundly immunocompromised from combina-
tion chemotherapy, and rituximab is often just one of the
many drugs received.108,109 There is only one well-studied
case of PML in ITP and the course was unusual with the
PML occurring more than 3 years after exposure to ritux-
imab.
The occurrence of late-onset (>4 weeks after treatment)
neutropenia has been described in patients treated with
rituximab for both malignant110 and non-malignant condi-
tions,111,112 including a few ITP patients.40 Most cases
appear to be self-limiting and resolve without issue,113 and
according to some authors retreatment with rituximab is
safe.86
Malignancies
Immunosuppression secondary to rituximab could
increase the risk of second primary malignancies. In large
follow-up studies, rituximab has not been shown to
increase the risk of cancer in patients with rheumatoid
arthritis,114 among non-Hodgkin lymphoma patients115 and
in patients with ANCA-associated vasculitis.116
No malignancies were reported in ITP by Arnold et al. in
a meta-analysis including more than 300 patients,42 or in
other studies,40,41,58 including combination studies with
dexamethasone.54,69,70 In other reports nearly 3-4% of
patients developed a second primary malignancy after
having received rituximab for ITP, but the low percentage
and the heterogeneity of the neoplasia led the authors to
conclude that a causative relationship with rituximab
could not be assessed.39,44,56
Use of rituximab in children
Following the development of rituximab for adults with
ITP, studies soon migrated to pediatric patients (Table 4).
The first large series was reported in 2005 and included
24 chronic ITP patients who were refractory to or relapsed
after previous treatments. The ORR to “standard-dose”
rituximab was 78%, with a 63% CR rate and an overall
sustained response rate of 37%.117
The first prospective phase I/II study of rituximab in
children and adolescents with chronic ITP included 36
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patients with severe refractory ITP or Evans syndrome
treated with “standard-dose” rituximab. After a follow up
of 1 year, 31% of them maintained a platelet count
>50x109/L.118,119
A systematic review including 14 studies with a total of
323 pediatric ITP patients reported a pooled response rate
of 68%, and a pooled CR rate of 39%, with a median
duration of response of 12.8 months.120
“Low-dose” rituximab has also been tested in children
with ITP: Taube et al. explored the efficacy of a single dose
of rituximab (375 mg/m2) in 22 patients with chronic ITP;
the ORR was 59%, with a 27% CR rate, and 36% of
patients maintained a long-term remission (median dura-
tion of remission 13.5 months; range 2-16 months).121
Oved et al. explored the addition of three 4-day cycles of
dexamethasone (28 mg/m2) to “standard-dose” rituximab
in 33 children with persistent/chronic ITP. The ORR was
close to 50%, and 62% of the responders maintained the
remission for a median of 35.5 months.122 
Factors predictive of response were also sought in chil-
dren. Bennett et al.118 found a weak association between
response and Evans syndrome, female sex and black race.
Parodi and colleagues performed a retrospective study
including 49 children (77% with chronic ITP) treated with
“standard-dose” rituximab (ORR 69%, 60% relapse-free
survival at 36 months), and found a significantly higher
probability of relapse-free survival in males aged >14
years and females aged >12 years (88.9% vs. 56.7%), in
patients who achieved a CR (70.2% vs. 25%) and in
patients who achieved the response within 20 days of
treatment (73.7% vs. 22%).123
Among 80 pediatric patients with chronic ITP treated
with rituximab (ORR 64%), Grace et al. found a higher
response rate in patients who had previously responded to
steroids (87.5% vs. 47.9%) and in those with secondary
ITP (89.5% vs. 55.7%).124
In a study by Oved et al.,122 female adolescents with ITP
lasting less than 24 months had a higher sustained remis-
sion rate (47%) than that of either the entire group (27%)
or the male patients (7%).
The drug is usually well tolerated also in children, with
a toxicity profile superimposable to that of adult patients
in terms of immediate and long-term toxicity.117,118,125,40,123
Significant hypogammaglobulinemia was observed in
15% of patients treated with the combination of ritux-
imab and dexamethasone,122 although this adverse event
was transient.
The reported rate of serum sickness was higher in pedi-
atric patients than in adults, particularly in the first series,
occurring in up to 10% of the former.117,118 Clinical mani-
festations ranged from severe to mild. Laboratory confir-
mation can be sought by checking levels of C3 and C4; of
note, certain pediatric patients may have a congenitally
low C4 level (which may predispose to ITP) and C4 levels
should, therefore, be checked prior to rituximab treat-
ment.
Discussion 
Twenty years after the first use of rituximab in ITP, pub-
lished studies show an ORR of nearly 60% and a CR rate
of 50%. Long-term remissions occur in 20-30% of
patients, with slightly different outcomes possibly related
to different selection of populations of patients.
In the interpretation of the results it is worth noting that
Table 4. Rituximab in children. 
Author                Rituximab dose     Number         Median age          F:M              ITP phase                ORR         12 months      24 months      36 months      Last follow-up
                                (mg/m2)        of patients     years (range)                                                            (CR)
Wang 2005117                375 mg/m2                 24                  12 (2-19)           58%:42%               Chronic                    78%*                  NA                       NA                      NA                         NA
                                      x 4 weekly                                                                                                                                    (63%)
Taube 2005121              375 mg/m2                 22               5.8 (2.5-15.2)       64%:36%               Chronic                    59%*                  NA                       NA                      NA                         NA
                                                                                                                                                                                              (32%)
Bennett 2006118           375 mg/m2                 36              11.2 (2.6-18.3)      42%:58%               Chronic                    31%°                 31%                      NA                      NA                         NA
& Mueller 2009119          x 4 weekly
Parodi 2009123              375 mg/m2
                                      x 4 weekly                 49               7.4 (0.7-17.6)       67%: 33%          77% chronic          69%° (53%)            NA                       NA                     60%                        NA
Grace 2012124                     NA                        80                7.5 (4.9-12)         56%:44%               Chronic                    64%°                  NA                       NA                      NA                         NA
Patel 201240                 375 mg/m2                 66                  12 (2-17)           61%:39%               Median                    57%°                 33%                      NA                      NA               26% at 5 years
                                     x 4 weekly                                                                                               duration of 
                                                                                                                                                     ITP 20 months
                                                                                                                                                (1 month – 9 years)
Matsubara 2014125      375 mg/m2                 22              4.2 (0.25-11.6)      50%:50%               Median                    50%*                 27%                     18%                     NA               14% at 5 years
                                      x 4 weekly                                                                                               duration of                (41%)
                                                                                                                                                    ITP 18.5 months 
                                                                                                                                                   (2 – 120 months)                
Oved 2017122                Rituximab                 33                  11 (1-17)           58%:42%            Persistent/                  48%°                  NA                       NA                      NA             27% at a median 
                                      375 mg/m2                                                                                               chronic ITP
                                    x 4 weekly +                                                                                                                                                                                                                                        FU  of 35 months
                                 dexamethasone                                                                                                                                                                                                                                       (range 10-58)
                                   28 mg/m2 days 
                                 1-4; 15-18; 29-32                                           
F:M: female to male ratio;  ITP: immune thrombocytopenia; ORR: overall response rate; CR: complete response; NA: not available; FU: follow-up; Response rates are calculated using as denomina-
tor all the patients treated with rituximab. *response = platelet count ≥30x109/L; °response = platelet count ≥50 x 109/L; §sustained platelet count over 50x109/L in 4 consecutive weeks.
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heterogeneous criteria for response were adopted across
different studies (according to older or updated criteria);
moreover, older studies included mostly chronic, pluri-
refractory patients, while in the more recent studies
patients with newly diagnosed/persistent ITP were also
included. Finally, the ability to compare studies is often
only partial because of different follow-up periods. 
The data from placebo-controlled studies seem discour-
aging, but some considerations should be made: in the
experimental treatment and placebo arms, patients were
allowed to continue corticosteroid therapy, which could
have biased the results: in the placebo arms the ORR were
67% (39% CR)48 and 73% (46% CR).47 Probably a more
meaningful observation is that the median time to relapse
in patients who achieved an overall response was 36
weeks in the rituximab group and 7 weeks in the placebo
group.48
The main criticism that only 20% to 30% of patients
achieve long-term remission for more than 3-5 years
deserves further consideration. The main “error” was
probably the mistaken belief that rituximab could repre-
sent the medical substitute of splenectomy: a single treat-
ment administered once in a lifetime that could definitive-
ly cure many or even most patients with ITP. In some
groups of patients, it is worth considering that even a sus-
tained response of 12-18 months can have a significant,
positive effect on a patient’s quality of life: during this
period of time, they do not have to take any ITP medica-
tion and can avoid frequent hospital checks. 
Furthermore, several clinical studies found that in young
women a course of rituximab administered before the
chronic phase (ITP duration <12 months) can lead to
response rates and at least mid-term remission rates com-
parable to those obtained with splenectomy. This finding
suggests that at least in some selected patients the treat-
ment outcome may be much better. 
Retreatment with rituximab is effective in most cases,
especially in patients who maintained the preceding
remission for more than 12 months. 
Biomarkers predictive of response, including the contro-
versial role of anti-platelet antibody testing, are still lack-
ing and further studies are needed for their establishment
and subsequent application in clinical practice.
The efficacy and safety of combinations of treatment
with rituximab and other agents, such as thromboietin-
receptor agonists, immunosuppressive agents, agents tar-
geting plasma cells or yet others, need to be better evalu-
ated and proven in comparison studies with rituximab
monotherapy.
As far as concerns different rituximab doses, compar-
isons between the “standard dose” and “rheumatoid
arthritis dose” did not reveal different results in terms of
efficacy and toxicity. Low-dose rituximab could be equal-
ly effective, although prospective studies comparing the
standard dose and low doses are lacking.  
Rituximab is a well-tolerated drug; serious side effects
are extremely rare and life-threatening infectious compli-
cations are usually only seen in patients with other con-
comitant causes of immunodeficiency.
Conclusions
In conclusion, based on what has been published in the
last 20 years, it is still difficult to give clear indications on
when, to whom and how rituximab should be adminis-
tered. In 2019, the choice of rituximab over other treat-
ment options has to be weighed considering the individ-
ual patient’s features and expectations, the disease’s char-
acteristics, the availability of the drug and the single cen-
ter’s experience.
The authors of this review think that rituximab still rep-
resents a valuable therapeutic option for patients with ITP
and, based on current knowledge, believe that it should be
considered especially (although not exclusively) at an early
stage of the disease, as second- or third-line therapy, in
young patients (particularly young women) and in
patients treated with curative purposes.
E. Lucchini et al.
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